These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32248771)

  • 21. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
    Zinkstok SM; Roos YB;
    Lancet; 2012 Aug; 380(9843):731-7. PubMed ID: 22748820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes with Alteplase at 0.6 mg/kg in Clinical Practice: THAWS2 Study.
    Yoshimura S; Koga M; Okada T; Inoue M; Miwa K; Fukuda-Doi M; Kondo R; Inoue T; Ichijo M; Ohtaki M; Nagakane Y; Itabashi R; Sakai N; Kimura K; Kamiyama K; Shiokawa Y; Yagita Y; Iwama T; Yakushiji Y; Kusumi M; Yamaki T; Uemura J; Yasuura A; Noshiro S; Fukunaga D; Yazawa Y; Aoki J; Yoshikawa M; Ihara M; Toyoda K;
    Cerebrovasc Dis; 2024; 53(1):46-53. PubMed ID: 37263235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial.
    Minhas JS; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Donnan GA; Kim JS; Lavados PM; Lee TH; Martins SCO; Olavarría VV; Pandian JD; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Thang NH; Wang JG; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Cerebrovasc Dis; 2018; 45(5-6):213-220. PubMed ID: 29705803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
    Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombolysis Outcomes in Acute Ischemic Stroke by Fluid-Attenuated Inversion Recovery Hyperintense Arteries.
    Zhou Z; Yoshimura S; Delcourt C; Lindley RI; You S; Malavera A; Torii-Yoshimura T; Carcel C; Wang X; Chen X; Parsons MW; Demchuk AM; Wardlaw JM; Mair G; Robinson TG; Chalmers J; Xu J; Anderson CS
    Stroke; 2020 Jul; 51(7):2240-2243. PubMed ID: 32568636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.
    Campbell BCV; Ma H; Parsons MW; Churilov L; Yassi N; Kleinig TJ; Hsu CY; Dewey HM; Butcher KS; Yan B; Desmond PM; Wijeratne T; Curtze S; Barber PA; De Silva DA; Thijs V; Levi CR; Bladin CF; Sharma G; Bivard A; Donnan GA; Davis SM
    JAMA Neurol; 2021 Feb; 78(2):236-240. PubMed ID: 33137171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial.
    Koga M; Inoue M; Miwa K; Yoshimura S; Fukuda-Doi M; Aoki J; Asakura K; Kanzawa T; Ohtaki M; Kamiyama K; Yakushiji Y; Igarashi S; Doijiri R; Ito Y; Takagi Y; Sasaki M; Kitazono T; Kimura K; Minematsu K; Yamamoto H; Toyoda K
    J Atheroscler Thromb; 2023 Jan; 30(1):15-22. PubMed ID: 35197420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
    Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
    Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
    Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results.
    Schwamm LH; Wu O; Song SS; Latour LL; Ford AL; Hsia AW; Muzikansky A; Betensky RA; Yoo AJ; Lev MH; Boulouis G; Lauer A; Cougo P; Copen WA; Harris GJ; Warach S;
    Ann Neurol; 2018 May; 83(5):980-993. PubMed ID: 29689135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
    Ma H; Campbell BCV; Parsons MW; Churilov L; Levi CR; Hsu C; Kleinig TJ; Wijeratne T; Curtze S; Dewey HM; Miteff F; Tsai CH; Lee JT; Phan TG; Mahant N; Sun MC; Krause M; Sturm J; Grimley R; Chen CH; Hu CJ; Wong AA; Field D; Sun Y; Barber PA; Sabet A; Jannes J; Jeng JS; Clissold B; Markus R; Lin CH; Lien LM; Bladin CF; Christensen S; Yassi N; Sharma G; Bivard A; Desmond PM; Yan B; Mitchell PJ; Thijs V; Carey L; Meretoja A; Davis SM; Donnan GA;
    N Engl J Med; 2019 May; 380(19):1795-1803. PubMed ID: 31067369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous Thrombolysis Guided by Perfusion CT with Alteplase in >4.5 Hours from Stroke Onset.
    Medina-Rodriguez M; Millan-Vazquez M; Zapata-Arriaza E; Escudero I; Pardo-Galiana B; Cabezas-Rodriguez JA; Lebrato-Hernandez L; Ortega-Quintanilla J; de Albóniga-Chindurza A; Ocete-Perez RF; Jurado-Serrano J; Gonzalez-Garcia A; Cayuela A; Moniche F
    Cerebrovasc Dis; 2020; 49(3):328-333. PubMed ID: 32615572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
    Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W;
    Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase.
    Hirano T; Sasaki M; Tomura N; Ito Y; Kobayashi S;
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):898-902. PubMed ID: 21737309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.